New ATC 5th levels
List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.
Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.
ATC code | ATC level name | Deadline for objection to temporary codes | Implementation in ATC/DDD index |
---|---|---|---|
C01EB25 | acoramidis | Final | 2025 |
S01XA32 | avacincaptad pegol | Final | 2025 |
J01DF51 | aztreonam and beta-lactamase inhibitor | Final | 2025 |
L01XY04 | bifikafusp alfa and onfekafusp alfa | 01.09.2024 | 2025 |
S01EA55 | brimonidine and ripasudil | Final | 2025 |
L01XX86 | calaspargase pegol | 01.09.2024 | 2025 |
L01XX82 | darinaparsin | 01.09.2024 | 2025 |
L01FX35 | datopotamab deruxtecan | 01.09.2024 | 2025 |
R07AX33 | deutivacaftor, tezacaftor and vanzacaftor | 01.09.2024 | 2025 |
S01XA33 | diquafosol | 01.09.2024 | 2025 |
A10XX02 | donislecel | Final | 2025 |
B03XA10 | efepoetin alfa | Final | 2025 |
L01FX32 | elranatamab | Final | 2025 |
J05AG07 | elsulfavirine | Final | 2025 |
J05AR29 | emtricitabine, tenofovir alafenamide and dolutegravir | Final | 2025 |
A10BK09 | enavogliflozin | Final | 2025 |
C08DA03 | etripamil | Final | 2025 |
A02BC10 | fexuprazan | Final | 2025 |
B02BD17 | fidanacogene elaparvovec | Final | 2025 |
V09IX18 | flotufolastat (18F) | Final | 2025 |
J04AC02 | ftivazide | Final | 2025 |
B06AC07 | garadacimab | Final | 2025 |
A10BD30 | gemigliptin and dapagliflozin | Final | 2025 |
J01XX13 | gepotidacin | Final | 2025 |
L04AC26 | goflikicept | Final | 2025 |
A16AX24 | govorestat | Final | 2025 |
L01XX85 | idroxioleic acid | 01.09.2024 | 2025 |
A02BC11 | ilaprazole | Final | 2025 |
J07BB05 | influenza, RNA-based vaccine | Final | 2025 |
V10XA04 | iodine (131I) apamistamab | Final | 2025 |
J05AX33 | labuvirtide | 01.09.2024 | 2025 |
S01EE52 | latanoprost and dorzolamide | Final | 2025 |
S01AX25 | lotilaner | Final | 2025 |
M01AE19 | loxoprofen | Final | 2025 |
B02BX11 | marstacimab | 01.09.2024 | 2025 |
L03AX24 | mavorixafor | 01.09.2024 | 2025 |
J07AH11 | meningococcus A,B,C,Y,W-135, pentavalent purified polysaccharides antigen conjugated and factor H binding protein | Final | 2025 |
L01EE05 | mirdametinib | 01.09.2024 | 2025 |
B03XA09 | molidustat | Final | 2025 |
L03AX23 | motixafortide | 01.09.2024 | 2025 |
J05AP14 | narlaprevir | Final | 2025 |
A16AX25 | nedosiran | 01.09.2024 | 2025 |
L01XX81 | nirogacestat | Final | 2025 |
L01XL12 | obecabtagene autoleucel | 01.09.2024 | 2025 |
L01FX34 | odronextamab | Final | 2025 |
J01RA17 | ofloxacin and nitazoxanide | Final | 2025 |
J01RA18 | ofloxacin and tinidazole | Final | 2025 |
L01XM03 | olutasidenib | Final | 2025 |
N07XX25 | omaveloxolone | 01.09.2024 | 2025 |
N07BB06 | ondelopran | Final | 2025 |
L01XX83 | para-toluenesulfonamide | 01.09.2024 | 2025 |
L01FX36 | patritumab deruxtecan | 01.09.2024 | 2025 |
L01XX84 | pelabresib | 01.09.2024 | 2025 |
M01AE20 | pelubiprofen | 01.09.2024 | 2025 |
C10BA13 | pitavastatin and ezetimibe | Final | 2025 |
L04AJ11 | pozelimab | 01.09.2024 | 2025 |
J04AM09 | pyrazinamide, ethambutol, isoniazid and lomefloxacin | Final | 2025 |
J04AM10 | pyrazinamide, ethambutol, protionamide and lomefloxacin | Final | 2025 |
L04AA60 | remibrutinib | Final | 2025 |
L01EX28 | repotrectinib | Final | 2025 |
L01XH07 | resminostat | Final | 2025 |
J05AX32 | riamilovir | Final | 2025 |
J04AM11 | rifabutin, pyrazinamide and protionamide | Final | 2025 |
J04AM12 | rifampicin, pyrazinamide, isoniazid and levofloxacin | Final | 2025 |
C10BX22 | rosuvastatin and nebivolol | Final | 2025 |
P01AB08 | satranidazole | Final | 2025 |
B06AC08 | sebetralstat | 01.09.2024 | 2025 |
A05AX07 | seladelpar | 01.09.2024 | 2025 |
L04AG17 | seniprutug | Final | 2025 |
J06BD09 | sipavibart | Final | 2025 |
C02KX06 | sotatercept | Final | 2025 |
C09XX01 | sparsentan | Final | 2025 |
L01FX33 | tarlatamab | Final | 2025 |
L04AX10 | tegomil fumarate | 01.09.2024 | 2025 |
J01RA19 | tetracycline and nystatin | Final | 2025 |
P01AB53 | tinidazole and diloxanide | Final | 2025 |
L01EL06 | tirabrutinib | Final | 2025 |
N07XX24 | trofinetide | Final | 2025 |
L01XH06 | tucidinostat | Final | 2025 |
L01DC05 | utidelone | Final | 2025 |
L04AJ10 | vilobelimab | Final | 2025 |
L01XM04 | vorasidenib | Final | 2025 |
V04CX12 | xenon | Final | 2025 |
L01FD07 | zanidatamab | Final | 2025 |
N02CD08 | zavegepant | Final | 2025 |
L01FX31 | zolbetuximab | Final | 2025 |
N06AX31 | zuranolone | Final | 2025 |
Last updated: 2024-05-07